BioSpace News Archive

Tango Therapeutics, a biotechnology company creating novel, targeted medicines for specific cancer subtypes, today announced the addition of three experienced leaders with deep backgrounds in personalized cancer research, drug discovery and development to the board of directors.

Quanterix Corporation announced its industry-leading single molecule array, or Simoa, technology has achieved enhanced sensitivity for the detection of acute HIV infection relative to currently approved fourth-generation antigen-antibody (Ag/Ab) combination (combo) and stand-alone p24 assays.

The Company is adding Devon Park, doubling its laboratory footprint in Penn.

Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today that Rosana Kapeller has resigned from the company after more than eight years of success to explore an executive leadership role.

HemaCare Corporation announced operational highlights and financial results for the year ended December 31, 2017.

Clovis Oncology Inc. announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations.

InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced enrollment of the first patient in its Phase IIb study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS).

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018, before the open of the U.S. financial markets.

BioScrip, Inc. (NASDAQ: BIOS) (“BioScrip” or the “Company”), the largest independent national provider of infusion and home care management solutions, today announced its preliminary 2017 financial results and provided financial guidance for 2018, subject to the completion of the Company’s accounting review described below.

The Sentara Cancer Center will provide a centralized hub of services for compassionate, personalized, and convenient cancer care